US FDA Will Leverage Current Clinical Trial Data In Deciding On Post-COVID Flexibilities
Executive Summary
Oncology Center of Excellence’s Paul Kluetz says agency intends to explore the effects of decentralization, remote assessments and other approaches adopted mid-stream on safety evaluations, missing data and endpoint variability.
You may also be interested in...
US FDA Oncology Center Wants Trial Datasets Flagged As Remote Or In-Person Assessments
Agency wants to use pandemic-interrupted clinical trials to gauge how decentralized approaches impacted study integrity and to inform prospective use of such designs post-COVID.
PDUFA VII Talks Begin With Similar Goals For Industry, US FDA
Both sides want enhancements to deal with growth in cell and gene therapy, as well as work on regulatory decision tools and finance issues.
Preventing Missing Data Among Concerns In US FDA’s Guidance On COVID-19 Symptom Assessment
Investigators should plan to find the vital status of discontinued patients, guidances states. Participants need frequent reminders to complete PRO instruments, agency recommends.